Developments in immunosuppression.
Antibodies, Monoclonal
/ therapeutic use
Antibodies, Monoclonal, Humanized
/ therapeutic use
Everolimus
/ therapeutic use
Graft Rejection
/ immunology
Humans
Immunosuppression Therapy
/ methods
Immunosuppressive Agents
/ therapeutic use
Kidney Transplantation
/ methods
Randomized Controlled Trials as Topic
Transplant Recipients
/ statistics & numerical data
Journal
Current opinion in organ transplantation
ISSN: 1531-7013
Titre abrégé: Curr Opin Organ Transplant
Pays: United States
ID NLM: 9717388
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
pubmed:
18
12
2020
medline:
27
7
2021
entrez:
17
12
2020
Statut:
ppublish
Résumé
In this review, we discuss achievements in immunosuppression in kidney transplant recipients published at last 18 months. Results of recent trials with everolimus in low-risk primary kidney transplant recipients suggest that lowTAC/EVR combination is noninferior and CMV and BKV viral infections are less frequent to standTAC/MPA. Iscalimab monoclonal antibody, which prevents CD40 to CD154 binding, has just recently entered phase II clinical studies in kidney transplantation. Eculizumab, anti-C5 monoclonal antobody was recently shown to improve outcomes in DSA+ living-donor kidney transplant recipients requiring pretransplant desensitization because of crossmatch positivity. Proximal complement C1 inhibition in patients with antibody-mediated rejection was studied in several phase I trials. Recent knowledge creates a path towards future immunosuppression success in sensitized recipients and in those in high risk of viral infections or CNI nephrotoxicity.
Identifiants
pubmed: 33332922
doi: 10.1097/MOT.0000000000000844
pii: 00075200-202102000-00014
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
Immunosuppressive Agents
0
iscalimab
0628T707D0
Everolimus
9HW64Q8G6G
eculizumab
A3ULP0F556
Banques de données
ClinicalTrials.gov
['NCT03221842']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
91-96Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Références
Sommerer C, Suwelack B, Dragun D, et al. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients. Kidney Int 2019; 96:231–244.
Pascual J, Berger SP, Witzke O, et al. TRANSFORM Investigators. Everolimus with reduced calcineurin inhibitor exposure in renal transplantation. J Am Soc Nephrol 2018; 29:1979–1991.
Qazi Y, Shaffer D, Kaplan B, et al. Efficacy and safety of everolimus plus low-dose tacrolimus versus mycophenolate mofetil plus standard-dose tacrolimus in de novo renal transplant recipients: 12-month data. Am J Transplant 2017; 17:1358–1369.
Tedesco-Silva H, Pascual J, Viklicky O, et al. TRANSFORM Investigators. Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: an analysis from the randomized TRANSFORM Study. Transplantation 2019; 103:1953–1963.
Berger SP, Sommerer C, Witzke O, et al. TRANSFORM investigators. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. Am J Transplant 2019; 19:3018–3034.
Ferreira AN, Felipe CR, Cristelli M, et al. Prospective randomized study comparing everolimus and mycophenolate sodium in de novo kidney transplant recipients from expanded criteria deceased donor. Transpl Int 2019; 32:1127–1143.
Chadban S, Tedesco-Silva H. ATHENA: wisdom and warfare in defining the role of de novo mTOR inhibition in kidney transplantation. Kidney Int 2019; 96:27–30.
Archdeacon P, Dixon C, Belen O, et al. Summary of the US FDA approval of belatacept. Am J Transplant 2012; 12:554–562.
Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 2016; 374:333–343.
Woodle ES, Kaufman DB, Shields AR, et al. BEST Study Group. Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: a prospective, randomized multicenter trial. Am J Transplant 2020; 20:1039–1055.
Burghuber CK, Manook M, Ezekian B, et al. Dual targeting: combining costimulation blockade and bortezomib to permit kidney transplantation in sensitized recipients. Am J Transplant 2019; 19:724–736.
Parsons RF, Zahid A, Bumb S, et al. The impact of belatacept on third-party HLA alloantibodies in highly sensitized kidney transplant recipients. Am J Transplant 2020; 20:573–581.
Kumar D, Raynaud M, Chang J, et al. Impact of belatacept conversion on renal function, histology and gene expression in kidney transplant patients with chronic active antibody-mediated rejection. Transplantation 2020; [Epub ahead of print].
Kim SC, Wakwe W, Higginbotham LB, et al. Fc-silent anti-CD154 domain antibody effectively prevents nonhuman primate renal allograft rejection. Am J Transplant 2017; 17:1182–1192.
Espie P, He Y, Koo P, et al. First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody. Am J Transplant 2020; 20:463–473.
Cernoch M, Viklicky O. Complement in kidney transplantation. Front Med (Lausanne) 2017; 4:66.
Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368:2169–2181.
Glotz D, Russ G, Rostaing L, et al. C10-002 Study Group. Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies. Am J Transplant 2019; 19:2865–2875.
Marks WH, Mamode N, Montgomery RA, et al. C10-001 Study Group. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial. Am J Transplant 2019; 19:2876–2888.
Tan EK, Bentall A, Dean PG, et al. Use of eculizumab for active antibody-mediated rejection that occurs early postkidney transplantation: a consecutive series of 15 cases. Transplantation 2019; 103:2397–2404.
Schinstock CA, Bentall AJ, Smith BH, et al. Long-term outcomes of eculizumab-treated positive crossmatch recipients: allograft survival, histologic findings, and natural history of the donor-specific antibodies. Am J Transplant 2019; 19:1671–1683.
Cornell LD, Schinstock CA, Gandhi MJ, et al. Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. Am J Transplant 2015; 15:1293–1302.
Viglietti D, Gosset C, Loupy A, et al. C1 inhibitor in acute antibody-mediated rejection nonresponsive to conventional therapy in kidney transplant recipients: a pilot study. Am J Transplant 2016; 16:1596–1603.
Montgomery RA, Orandi BJ, Racusen L, et al. Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: results of a randomized double-blind placebo-controlled pilot study. Am J Transplant 2016; 16:3468–3478.
Muhlbacher J, Jilma B, Wahrmann M, et al. Blockade of HLA antibody-triggered classical complement activation in sera from subjects dosed with the anti-C1 s monoclonal antibody TNT009-results from a randomized first-in-human phase 1 trial. Transplantation 2017; 101:2410–2418.
Eskandary F, Jilma B, Muhlbacher J, et al. Anti-C1 s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial. Am J Transplant 2018; 18:916–926.
Winstedt L, Jarnum S, Nordahl EA, et al. Complete removal of extracellular IgG antibodies in a randomized dose-escalation phase i study with the bacterial enzyme IdeS--a novel therapeutic opportunity. PLoS One 2015; 10:e0132011.
Jordan SC, Lorant T, Choi J, et al. IgG endopeptidase in highly sensitized patients undergoing transplantation. N Engl J Med 2017; 377:442–453.
Lonze BE, Tatapudi VS, Weldon EP, et al. IdeS (imlifidase): a novel agent that cleaves human IgG and permits successful kidney transplantation across high-strength donor-specific antibody. Ann Surg 2018; 268:488–496.
Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA 2018; 320:1360–1372.
Jordan SC, Choi J, Kim I, et al. Interleukin-6, a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: therapeutic implications of IL-6 receptor blockade. Transplantation 2017; 101:32–44.
Choi J, Aubert O, Vo A, et al. Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant 2017; 17:2381–2389.
Shin BH, Everly MJ, Zhang H, et al. Impact of tocilizumab (anti-IL-6R) treatment on immunoglobulins and anti-HLA antibodies in kidney transplant patients with chronic antibody-mediated rejection. Transplantation 2020; 104:856–863.
Lavacca A, Presta R, Gai C, et al. Early effects of first-line treatment with antiinterleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation. Clin Transplant 2020; 34:e13908.
Perez-Saez MJ, Blasco M, Redondo-Pachon D, et al. Spanish Society of Nephrology COVID-19 Group. Use of tocilizumab in kidney transplant recipients with COVID-19. Am J Transplant 2020; 10:
Weinblatt ME, Mease P, Mysler E, et al. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. Arthritis Rheumatol 2015; 67:2591–2600.
Mease PJ, Gottlieb AB, Berman A, et al. The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis. Arthritis Rheumatol 2016; 68:2163–2173.
Eskandary F, Durr M, Budde K, et al. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial. Trials 2019; 20:37.
Navarra SV, Guzman RM, Gallacher AE, et al. BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:721–731.
Banham GD, Flint SM, Torpey N, et al. Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial. Lancet 2018; 391:2619–2630.
Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2016; 375:754–766.
van de Donk N, Richardson PG. Malavasi F: CD38 antibodies in multiple myeloma: back to the future. Blood 2018; 131:13–29.
Doberer K, Klager J, Gualdoni GA, et al. CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection. Transplantation 2020; [Epub ahead of print].
Kwun J, Matignon M, Manook M, et al. Daratumumab in sensitized kidney transplantation: potentials and limitations of experimental and clinical use. J Am Soc Nephrol 2019; 30:1206–1219.
Bohmig GA, Eskandary F, Doberer K, et al. The therapeutic challenge of late antibody-mediated kidney allograft rejection. Transpl Int 2019; 32:775–788.